Abstract
The cellular identity of pancreatic polypeptide (Ppy)-expressing γ-cells, one of the rarest pancreatic islet cell-type, remains elusive. Within islets, glucagon and somatostatin, released respectively from α- and δ-cells, modulate the secretion of insulin by β-cells. Dysregulation of insulin production raises blood glucose levels, leading to diabetes onset. Here, we present the genetic signature of human and mouse γ-cells. Using different approaches, we identified a set of genes and pathways defining their functional identity. We found that the γ-cell population is heterogeneous, with subsets of cells producing another hormone in addition to Ppy. These bihormonal cells share identity markers typical of the other islet cell-types. In mice, Ppy gene inactivation or conditional γ-cell ablation did not alter glycemia nor body weight. Interestingly, upon β-cell injury induction, γ-cells exhibited gene expression changes and some of them engaged insulin production, like α- and δ-cells. In conclusion, we provide a comprehensive characterization of γ-cells and highlight their plasticity and therapeutic potential.
Subject terms: Cell biology, Diabetes, Islets of Langerhans, Diabetes
The cellular identity and function of the pancreatic polypeptide (Ppy)-producing γ-cells are incompletely understood. Here the authors show that these cells are heterogeneous and display adaptive plasticity to engage in insulin production following β-cell injury, but loss of the Ppy gene or γ-cells in mice does not affect weight or glycemia under basal conditions.
Introduction
Searching for precise schemes to classify the hundreds of cell-types that compose an organism, recent advances in genetic and cellular analyses have expanded our understanding of the cell identity concept. Striking heterogeneity has been reported in what used to be considered homogeneous cell populations1,2, and new information continues to emerge from different cell systems. In particular, for endocrine cells, the production of specific hormones with highly specialized physiological functions form the basis of their identity. Various genetic pathways continue to be discovered that keep tight control of the production, processing and secretion of these endocrine hormones. Yet, surprisingly, there are reports of rare polyhormonal endocrine cells detected under different conditions. Bihormonal cells have been reported in the pituitary of fish, mice and humans3–5. Bihormonal cells have also been consistently reported during in vitro endocrine differentiation from human stem cells6,7. Polyhormonal cells are also present during mammalian pancreatic development (including humans) as well as in the adult endocrine pancreas, with increasing numbers in type 2 diabetic subjects8,9. Yet, these results suggest that bihormonal cells could be present in different endocrine organs and might have unexplored functions. In general, due to technical limitations, it has been hard to identify and characterize these types of cells. In our laboratory, using inducible cell lineage-tracing, we have reported that following near-total β-cell ablation, some 1–2% of mouse pancreatic islet cells engage insulin expression and become bihormonal10,11.
In the adult murine pancreas, the islets of Langerhans contain different endocrine types of cells: glucagon-secreting α-cells, insulin-secreting β-cells, somatostatin-secreting δ-cells and pancreatic polypeptide (Ppy)-secreting γ-cells. A delicate and highly complex orchestration of intra-islet paracrine interactions is thought to be essential to achieve robust secretory dynamics and blood glucose homeostasis. α-cell signaling, via glucagon or GLP-1, can directly stimulate insulin secretion12, while somatostatin directly inhibits insulin and glucagon secretion13–15. Providing balance, insulin indirectly inhibits glucagon release by promoting somatostatin secretion14. Given these and other observations, it is the consensus that hormone expression, and likely other key identity markers, is tightly controlled in each islet endocrine cell-type, with the near totality of cells producing only one of the main islet endocrine hormones16,17. Consequently, disruption of the pathways controlling endocrine cell-type identity and hormone production is thought to significantly impact islet cell function and might be one of the underlying causes of metabolic diseases like diabetes18.
Compared to the other islet cell types, little is known about the function of γ-cells or the Ppy hormone, mainly due to their scarcity and a lack of appropriate tools to analyze them. Ppy is thought to be an anorexigenic factor, controlling gastric emptying, pancreatic and gallbladder secretion, and intestinal peristalsis19–21. Repeated administration of Ppy can reduce food intake and gastric emptying22–25. Yet, gain- and loss-of-function studies in mice have given confounding results26–28, possibly due to compensatory mechanisms in the absence of Ppy signaling. Unfortunately, the mechanisms by which Ppy influences appetite, body weight and glucose homeostasis remain unclear. Yet, mounting evidence associates α- and δ-cells with the pathophysiology of diabetes, highlighting the role of islet non-β cells in blood glucose regulation29–31.
Here, we describe three transgenic mouse lines to i) lineage-trace and ii) ablate Ppy-expressing γ-cells, and iii) inactivate the Ppy gene. While performing the in-depth characterization of these cells, we discovered that a significant proportion of them also expresses glucagon, somatostatin or insulin at the mRNA and protein levels. Interestingly, these bihormonal cells are also present in adult human islets. Incidentally, the silencing of Ppy gene and the ablation γ-cells provide insights into Ppy and γ-cell functions in controlling glucose homeostasis under basal conditions.
Results
Generation of a transgenic line to lineage-trace Ppy+ cells and inactivate the Ppy gene
We developed a knock-in mouse line by replacing the coding sequence, in one allele, of the endogenous Ppy gene by the doxycycline (DOX)-dependent reverse transactivator (rtTA) coding region, using CRISPR technology (Fig. 1a, b). In these mice, rtTA expression is under the control of the endogenous Ppy gene regulatory elements. Triple Ppy-rtTA, TetO-Cre, Rosa26-STOP-YFP transgenic mice, termed Ppy-YFPi, were then generated to allow the inducible and irreversible expression of YFP upon DOX administration (Fig. 1c). This YFP tag allows to lineage-trace the Ppy-expressing cells (Fig. 1d, e;32,33). While no labeling was detected in absence of DOX (Supplementary Fig. 1; 1310 YFP+ cells scored; n = 3 mice; Source Data a), about 85% of Ppy-expressing cells were YFP-tagged in adult DOX-treated Ppy-YFPi mice either two weeks or ten months after DOX withdrawal (Fig. 1d, e; Source Data b). YFP-traced cells were Ppy-negative in Ppy-YFPi mice bearing the Ppy-rtTA transgene at homozygosity (Fig. 1f; Source Data b), confirming the inactivation of Ppy gene through the targeted insertion of rtTA and validating the specificity of the monoclonal Ppy antibodies (Supplementary Fig. 2). The distribution of YFP+ cells in DOX-treated Ppy-YFPi mice nicely recapitulates that of Ppy+ cells in wild type mice (WT) and humans, being more abundant in islets located in the head part of the pancreas34,35 (Supplementary Fig. 3, Source Data c).
Thus, the Ppy-YFPi transgenic line allows for an efficient, inducible and irreversible labeling of Ppy-expressing γ-cells, and for inactivating the Ppy gene, at homozygosity. For this reason, in all subsequent experiments aimed at characterizing the Ppy-expressing γ-cells, the Ppy-rtTA allele was maintained at the heterozygous state, so as to preserve monoallelic wild-type Ppy expression in Ppy-YFPi mice.
Adult γ-cells derive from embryonic Ppy-expressing cells
We sought to determine whether adult Ppy-expressing cells are exclusively generated during embryonic pancreas development or also at postnatal stages. We thus performed a pulse-and-chase experiment aimed at labeling Ppy+ cells irreversibly in developing embryos, by dispensing DOX to pregnant females from E7.5 (2 days before the beginning of pancreas development) up to end of gestation (Fig. 2a). YFP-tracked progeny was analyzed in thirty-days-old (P30) Ppy-YFPi mice.
Labeling of embryonic Ppy+ cells was efficient in Ppy-YFPi embryos (80% of Ppy+ cells were YFP-labeled in near-term fetuses (E18.5); Supplementary Fig. 4, Source Data d). We confirmed that YFP labeling activity ceased rapidly after DOX withdrawal by evaluating the residual Cre mRNA expression as readout of DOX clearance in islets of pregnant Ppy-YFPi females. We found that Cre mRNA levels dropped to background levels by two days after DOX withdrawal (Supplementary Fig. 4, Source Data d), suggesting that DOX activity lasts for only about 24 h after DOX removal. Based on this observation, we defined the duration of DOX activity as the pulse period plus one additional day of clearance (Fig. 2a).
Next, we assessed the origin of the adult Ppy-expressing cells (one-month after birth, P30). Following DOX administration during pancreas development (E7.5 to E19.5), the proportion of YFP-tagged Ppy-expressing cells at P30 was equivalent to the labeling efficiency (∼85%) observed in adult mice (Fig. 2b, Source Data e). This implies that adult γ-cells originate from Ppy+ cells appearing during pancreas development (i.e., prior to birth). Next, to evaluate Ppy+ cell emergence after P30, we extended the chase period until 9 months. Interestingly, we did not notice any decrease in the percentage of YFP-labeled adult cells if the chase period was extended up to 9 months after birth (Fig. 2b, Source Data e). Together, these observations indicate that adult γ-cells originate from Ppy+ cells appearing during pancreas development in utero, and that there is no evidence of postnatal Ppy+ cell neogenesis, at least nine months after birth.
We then evaluated whether the islet cells traced to an embryonic Ppy+ origin were producing other hormones instead of, or in addition to, Ppy. We found that some α- (glucagon+), δ- (somatostatin+) and β-cells (insulin+) were YFP-labeled in adult (one-month-old) Ppy-YFPi mice treated with DOX during gestation (Fig. 2c, d; Source Data e). Interestingly, some of these adult YFP+ cells also contained Ppy, and were thus bihormonal (Fig. 2c, d). We also observed embryonic YFP-traced cells co-expressing Ppy and other hormones during pancreas development (Supplementary Fig. 4). These results are consistent with previous observations showing that embryonic Ppy+ cells can express other hormones and could contribute to other islet lineages36–38.
γ-cells are a heterogeneous population of mono- and bihormonal cells
While Ppy+Gcg+ bihormonal cells were previously reported39,40, co-expression of Ppy protein with either somatostatin or insulin in embryonic or adult islet cells was debated38,41. We thus studied the Ppy-expressing cells in adult Ppy-YFPi mice giving DOX to adult animals. Administration of DOX to one-month or one-year-old Ppy-YFPi mice resulted in the labeling of cells containing Ppy alone or in combination with either glucagon (∼ 10% YFP+ cells were Gcg+), somatostatin (∼ 4% YFP+ cells were Sst+) or insulin (∼ 1% YFP+ cells were Ins+) (Fig. 3a, b; Supplementary Fig. 5; Source Data f). No significant statistical differences were found in the percentage of YFP-labeled hormone+ cells in one month or one-year-old mice (Fig. 3b; Source Data f). Ppy+Gcg+ and Ppy+Ins+ cells were the most and the least prevalent bihormonal cells, respectively (Fig. 3b; Source Data f). Co-expression of Ppy with Gcg, Sst and Ins was also observed in comparable proportions in non-transgenic wild-type mice (Fig. 3c, Supplementary Fig. 5; Source Data f). These observations show that a significant proportion of the adult γ-cell population is bihormonal and this remains constant even in aged mice.
Characterization of the transcriptional identity of monohormonal Ppy+ cells
To characterize the transcriptomic profile and, therefore, the cell identity of monohormonal Ppy-expressing γ-cells, we performed single-cell RNA-sequencing (scRNA-seq) on islet cells isolated from DOX-treated adult Ppy-YFPi mice (DOX at 1 month; analysis at 2 months) and sorted by FACS (Fig. 4a, Supplementary Fig. 6; YFP+ and YFP- fractions were collected). First, we removed putative doublet cells from our dataset using two independent tools, DoubletFinder42 and Scrublet43. Doing this, we accept the risk of eliminating actual bihormonal cells having a transitional hybrid (mixed) transcriptional profile. After doublet removal, we defined five populations based on unsupervised clustering (Cluster 1–5; Fig. 4b). Each endocrine cell-type cluster was identified using hormone expression: Gcg+ (Cluster 2), Ins2+ (Cluster 3), Ppy+ (Cluster 1), Sst+ (Cluster 4) and Ppy+ bihormonal (Cluster 5) (Fig. 4b, c; Supplementary Fig. 7; see methods). Cells surpassing the mathematically-defined threshold of expression of two hormones were defined as bihormonal (Supplementary Fig. 7; Source Data g). UMAP dimensional reduction showed that Ins2-, Gcg-, Sst- and Ppy-expressing cells were distributed in four main clouds with overlapping regions mainly where Ppy expression is located (Supplementary Fig. 7). Of note, the distribution of the YFP+ cell fraction tightly correlated with the Ppy+ cell localization (Supplementary Fig. 7). Only the hormone-expressing cells contained in their assigned cell-type cluster were considered for further analysis (i.e., only the Gcg-expressing cells located in Cluster 2 were studied while Gcg+ cells present in other clusters were excluded from the analysis as these latter transcriptionally resemble to other islet cells, but express Gcg; Fig. 4c).
To characterize monohormonal Ppy-expressing cells, we performed a pair-wise differential expression analysis between γ-cells and each of the three other monohormonal islet cell-types. The common upregulated genes in each of the endocrine cell comparisons (Ppy+ vs Gcg+, Ppy+ vs Sst+ and Ppy+ vs Ins2+) defined the monohormonal γ-cell identity (ID; Fig. 4d; Source Data h). We obtained 4 γ-ID genes, including Ppy and Pyy, but also Tspan8 and Folr1. α-, β- and δ-cell ID gene lists were also generated: 82 α-ID genes, 134 β-ID genes and 9 δ-ID genes were identified and they comprise characteristic cell markers such as Gcg, Ttr and Mafb in the α-specific genes; Ins1, Ins2 and Nkx6-1 in the β-specific genes; Sst and Hhex in the δ-specific genes (Source Data h). As single cell transcriptomics did not provide the necessary complexity to perform deep profiling, we next made use of bulk RNA sequencing of Ppy-expressing cells to more deeply profile these cells (see methods). In this dataset, 3240 γ-ID genes were obtained, including Ppy, Pyy and Folr1 (Fig. 4d, e; Source Data i). Despite Tspan8 expression was upregulated in Ppy-expressing cells, it did not pass the logFC threshold when Ppy+ cells were compared to Ins2+ cells (Fig. 4e). Within the bulk RNA-seq γ-ID, 195 transcription factors such as Arx, Ski and Fev, and 214 cell surface markers such as the Na+/K+ transporter subunit α-1 (Atp1a1) and the Epithelial cell adhesion molecule (Epcam) were identified (Fig. 4f).
Ppy-expressing γ-cells were also studied using Ingenuity Pathway Analysis (IPA) to better define their functional identity. To maximize the robustness of our analysis, DEGs between γ-cells and each of the other islet cell-types were calculated in the two independent islet RNA-seq datasets: the mouse single-cell RNA-seq and the mouse bulk RNA-seq. This resulted in hundreds or thousands of DEGs (Source Data j) for each of the three islet cell comparisons, which were then uploaded into IPA software. Modulated pathways were only considered if showing the very same regulation in both datasets (i.e., either upregulated or downregulated in both datasets; Source Data k). We identified 7 differentially-modulated γ-cell pathways compared to α-cells. Among these pathways, PI3K/AKT and Sirtuin Signaling Pathway were inhibited and activated, respectively. 46 pathways were modulated in γ-cells as compared to β-cells, including inhibition of the PI3K/AKT and AMPK pathways in γ-cells. Finally, 20 pathways were significantly regulated in γ-cells compared to δ-cells, including EIF2 activation (Source Data k). These pathways along with the ID genes define the functional signature of mouse γ-cells.
Bihormonal Ppy+ cells express identity genes of α-, δ- or β-cells
Next, we analyzed the identity of the mouse bihormonal Ppy+-cells as compared to the different monohormonal islet cell-types. By applying clustering analysis, we have in silico isolated the genuine hybrid bihormonal cells (black dots; Fig. 5a–c) from the bihormonal cells located in monohormonal cell clusters (colored dots; Fig. 5a–c). These latter cells were excluded as they transcriptionally resemble to monohormonal α-, β- and δ-cells, but express Ppy. Ppy+Gcg+, Ppy+Sst+ and Ppy+Ins2+ bihormonal cells represent 23.9%, 4.8% and 3.6% of the total Ppy+ cell population, respectively (Fig. 5d, Source Data g). Although present in higher proportion in the single-cell dataset, the abundance of each bihormonal Ppy+ subpopulation correlated with our observations at the protein level (Fig. 3 and Supplementary Fig. 5). Interestingly, most of the bihormonal Ppy+Gcg+, Ppy+Sst+ and Ppy+Ins2+ cells were scattered in UMAP in between each of the corresponding monohormonal populations (Fig. 5a–c), suggesting that these cells have a mixed transcriptomic signature. To test for this, we assessed how many of the α-, δ- and β-ID genes (Fig. 4 and Source Data i) were expressed in Ppy+Gcg+, Ppy+Sst+ and Ppy+Ins2+ bihormonal cells, respectively. Out of the 83 α-cell ID genes, 77 (94%) were present in the 199 DEGs detected in bihormonal Ppy+Gcg+ cells compared to monohormonal Ppy+ cells. Similarly, 6 (67%) out of the 9 δ-cell ID genes were allocated in the list of upregulated genes in Ppy+Sst+ cells. Finally, 35 (26%) out of the 134 β-cell ID genes were shared with the upregulated genes in Ppy+Ins2+ cells (Fig. 5e, f, Source Data l). Interestingly some markers such as Iapp and Chga were consistently enriched in the 3 different Ppy+ bihormonal cell types (Source Data m). Enrichment of the Iapp and Chga in the Ppy+Gcg+ and Ppy+Ins2+ populations was confirmed at protein level in islets of two independent wild-type mice (49.6% and 67.9% of Ppy+Gcg+ bihormonal cells vs 18.4% and 17.9% of the monohormonal Ppy+ cells contain Iapp and Chga, respectively; 87.4% and 93.8% of the Ppy+Ins+ bihormonal cells vs 8.1% and 28.1% of the monohormonal Ppy+ contain Iapp and Chga, respectively; minimum islets scored = 22; Supplementary Fig. 8 and Source Data m). These results indicate that Ppy+ bihormonal cells comprise a significant fraction of typical identity genes with monohormonal α-, δ- and β-cells, thus confirming a hybrid transcriptomic profile and not just simple dysregulation of hormone genes.
Human islets also contain bihormonal γ-cells
We next assessed whether bihormonal PPY-expressing γ-cells are also present in the human islet. We recently generated human scRNA-seq dataset from three independent non-diabetic human donors (van Gurp et al, submitted). Islets were sorted by FACS using an antibody-based protocol described previously44–46, allowing for γ- and δ-cell enrichment (Fig. 6c, Source Data n). Doublet removal and islet cell type identification were performed as described above. Cell-type-specific ID gene lists were calculated using the differentially expressed genes (DEGs) in γ-cells, as compared to the three other islet cell-types in conjunction. A total of 24 human γ-cell ID genes were identified (van Gurp et al, submitted). In order to assess the similarities between mouse and human PPY-expressing cells, we intersected the upregulated DEGs in PPY+ cells compared to GCG+, SST+ and INS+ independently in the three RNA-seq datasets: mouse single cell RNA-seq, mouse bulk RNA-seq and human single cell RNA-seq (Supplementary Fig. 9A; Source Data o). PPY, SCG2, TTR and GC were shared in both species between the three RNA-seq datasets (Supplementary Fig. 9A). The restricted number of genes shared between the 3 datasets is likely due to some inter-species variation as previously documented for some genes, like PYY expression47; but also to variation in resolution in the single cell RNA-sequencing techniques. This list of γ-cells genes shared between both species can be expanded to 24 genes when comparing upregulated genes between the human single cell RNA-seq and either the bulk or the single cell mouse datasets (Supplementary Fig. 9A; Source Data p). Using IPA, we defined the pathways modulated in human γ-cells and intersected with those observed in mouse γ-cells (Supplementary Fig. 9B–D; Source Data q). 3 and 15 pathways exhibit the very same modulation in mouse and human γ-cells, as compared to α-cells and β-cells, respectively (Supplementary Fig. 9C, D). No common pathway between both species was identified when comparing γ- and δ-cells (Source Data q).
Although with lower frequencies, the three types of bihormonal PPY+ cells were also detected in human PPY-expressing cells: 37 PPY-GCG+, 25 PPY-SST+ and 25 PPY-INS+ cells (Fig. 6c; Source Data n). PPY-GCG coexpressing cells were also detected at the protein level in pancreatic sections from the two non-diabetic donors analyzed (Fig. 6a, b, Source Data r). Deeper analysis of the PPY+ bihormonal cells by scRNA-seq, identified 70 upregulated genes in PPY-GCG bihormonal compared to monohormonal PPY cells (including the Ppy+ bihormonal-cell marker CHGA), out of which 26 (37.1%) were common with the 99 human α-cell ID genes (van Gurp et al, submitted). This includes functional α-cell markers such as GCG, TTR and MAFB (Fig. 6d, e; Source Data s). Similarly, PPY-SST and PPY-INS bihormonal cells shared some typical markers found in human δ- and β-cells, respectively (Supplementary Fig. 10; Source Data s).
These results indicate that bihormonal PPY-expressing cells also exist in adult human islets at both protein and mRNA level. These cells share common markers with the corresponding monohormonal cell types as we observed in mice.
Ppy gene inactivation and cell ablation do not affect blood glucose levels or body weight
Previous studies have suggested a role for Ppy on appetite suppression22–25. Here, we assessed the consequence of constitutive Ppy inactivation (gene knockout, “KO”) on blood glucose regulation in Ppy-rTA homozygous (HMZ) mice. No major alterations in body weight, glycemia and glucose tolerance (intraperitoneal glucose tolerance tests, “i.p.GTT”) were observed in Ppy-rtTA HMZ mice of both genders when compared with wild-type (WT) and Ppy-rtTA heterozygous (HTZ) mice (Fig. 7a–f; Source Data t). In addition, no differences in the glucose-stimulated insulin secretion capacity were detected between Ppy KO mice of both genders and wild-type (WT) or Ppy-rtTA HTZ mice (Fig. 7e, f; Source Data t). Because functional redundancy between NPY family members has been previously reported48,49, we assessed whether Pyy protein is expressed in γ-cells, as it is suggested by mRNA analyses (Fig. 7g and47; Source Data u). About 90% of the YFP+ population co-expressed Pyy in Ppy-rtTA HTZ mice (Fig. 7g; Source Data u). The expression level of Pyy in the islet was not impacted upon Ppy gene KO (Fig. 7h; Source Data u). While it cannot be excluded that Pyy may compensate for the lack of Ppy action, our results suggest that Ppy absence is well tolerated and has no impact on body weight or blood glucose regulation, at least under basal conditions.
As Ppy hormone inactivation did not impact on body weight evolution nor blood glucose regulation, we generated a knock-in mouse that enabled us to selectively ablate all Ppy-expressing cells. To do this, we replaced the coding sequence of the Ppy gene by the diphtheria toxin receptor (DTR; Supplementary Fig. 11A, B). In these KI mice, diphtheria toxin (DT) administration efficiently induced more than 99% γ-cell ablation 15 days and 3 months post-injection (Supplementary Fig. 11C; 0.004 Ppy+ cells per islet section were identified 15 days post-ablation; 0.1 Ppy+ cells per islet section were identified 3 months post-ablation; Source Data v). Similar to the Ppy inactivation mouse model, no alterations in body weight, glycemia and i.p.GTT were detected in mice lacking γ-cells (Supplementary Fig. 11D–I; Source Data v).
Although we cannot completely exclude that the remaining 1% γ-cells may release undefined factors that could be involved in blood glucose regulation, these results combined suggest that Ppy and the γ-cells are dispensable in basal conditions for blood glucose regulation.
Ppy-expressing cells efficiently engage insulin production
We previously reported that human primary α- and γ-cells can be reprogrammed to glucose-dependent insulin secretion when Pdx1 and MafA expression is induced44. In mice, adult α-cells also exhibit cell plasticity by starting insulin production upon β-cell destruction10. We thus explored whether γ-cells can spontaneously reprogram to insulin production in diabetic mice. Ppy-YFPi mice were crossed with RIP-DTR animals, in which the diphtheria toxin receptor (DTR) is borne on the surface of β-cells10 (Fig. 8a). β-cell loss was induced in DOX-treated Ppy-YFPi;RIP-DTR mice by DT administration (Fig. 8b). DT-treated mice became severely hyperglycemic one-week after β-cell ablation (Fig. 8C). The strong decrease in YFP-labeled Ins+ cells 5 days after DT (black vs green dots in Fig. 8e and d; Source Data w) indicates that pre-existing bihormonal Ppy+Ins+ cells were efficiently ablated together with β-cells upon DT. ~40% of the Ins+ cells were YFP-labeled 6 weeks post-DT, indicating that these cells are reprogrammed γ-cells that have started insulin production (Fig. 8f). Nearly all converted γ-cells (95.3% ± 0.1; n = 4; 103 Ins+YFP+Ppy- out of 108 Ins+YFP+ cells scored) did not have detectable levels of Ppy (inset in panel Fig. 8g; Source Data w). In total, only a small fraction (3%) of the adult γ-cell population had spontaneously engaged insulin production after β-cell loss (Fig. 8e, f; Source Data w), as previously reported for α-cell conversion in diabetic mice10. Interestingly, up to 40% of YFP-labeled γ-cells could be convinced to produce insulin when combined with ectopic Pdx1 expression in γ-cells and DT-induced β-cell loss (Supplementary Fig. 12; Source Data x). Together, these results indicate that mouse γ-cells exhibit a functional cell plasticity like α- and δ-cells, as we previously showed with human primary PPY-expressing cells.
Discussion
Using transgenic mouse lines for conditional cell lineage tracing and ablation, in combination with human islet flow cytometry sorting (FACS) techniques, we provide here a deep characterization of the genetic identity of the very elusive PPY-expressing γ-cell at the mRNA and protein levels. We have uncovered a seemingly distinct and significantly abundant population of bihormonal γ-cells in the adult mouse and human islet. We also determined that Ppy gene inactivation, or massive γ-cell ablation, has little or no impact on blood glucose homeostasis under basal conditions. Finally, our results show that γ-cells can also reprogram after massive β-cell ablation and, along with our previous reports10,11 show that in essence all non-β-cells have the capacity to produce insulin in vivo under the appropriate stress conditions, collectively contributing to β-cell regeneration.
The current consensus is that under physiological conditions essentially all adult islet cells are monohormonal, as dysregulation of hormone expression could lead to detrimental secretory dynamics. Yet, we found that about 15% of adult mouse γ-cells express an additional islet hormone at the protein level, as well as additional identity markers shared with other islet cell-types at the mRNA level. For instance, Ppy+Gcg+ cells expressed typical α-cell markers like Ttr and MafB. Ppy+Sst+ and Ppy+Ins2+ cells also expressed key δ- and β-cell markers (Hhex in Ppy+Sst+ cells and Nkx6.1 in Ppy+Ins+ cells, for instance). These observations indicate that the different Ppy+ bihormonal cells display hybrid transcriptional profiles (Figs. 4 and 5). Human γ-cells were also bihormonal, yet less frequently than in mice.
Future research should focus on the precise origin and functional role of these bihormonal Ppy+ cells, with new methodology needed to determine whether their bihormonal status is permanent or dynamic. We and others have reported the presence of Ppy+ bihormonal cells in developing mouse and human pancreas38,50,51. Therefore, bihormonal cells arise during development and are maintained, at least in part, after birth. In addition, a minor fraction of the postnatal bihormonal cells might originate from Ppy+ monohormonal γ-cells, or inversely, from α-, β- or δ-cells that initiate Ppy+ expression. At this point, more sophisticated bihormonal-cell tracing tools would be required to better study their origin and transitional dynamics.
Our results also provide further insight into the requisite of Ppy and γ-cells in blood glucose regulation. Despite the reported role of Ppy controlling appetite, here and in previous reports27, constitutive Ppy gene inactivation did not alter mouse body weight. Furthermore, glycemic monitoring did not reveal any affection on blood glucose homeostasis and glucose-stimulated insulin secretion (Fig. 7) under the conditions analyzed here. Of note, these results differ from the observations made in several Npyr knockout mouse models52,53, where the hypophagic effect of Ppy is absent. Inactivation of an Npy receptor affects the signaling pathways of all Npy peptides (Npy, Ppy and Pyy)54,55, resulting in a robust phenotype (reduced food intake and body weight). By contrast, Ppy inactivation affects Ppy signaling pathway specifically. It is possible that the appropriate experimental conditions have not been tested, as Ppy might have more of a fine-tuning role in response to significant islet secretory dysregulation due to severe stresses, like viral infections or prolonged fasting. Interestingly, previous reports have shown that male and females Ppy-deficient mice treated with high-fat diet display no change in body weight gain or body composition compared to wild-type littermates27. This observation is in line with the absence of phenotype in mice in which the hormone or the γ-cells were inactivated and ablated, respectively (Fig. 7 and Supplementary Fig. 11).
Alternatively, this lack of phenotype might be due to compensatory mechanisms that ensure residual Ppy signaling in Ppy KO mice. Several studies revealed that the Ppy gene originated from a duplication of the Pyy gene, and both genes are only 10 kb apart in mouse and human genomes56,57, which might be compatible with a transcriptional co-regulation. In line with this, we found that mouse γ-cells do express significant levels of Pyy, both in wild-type and Ppy-KO mice (Fig. 7). As both proteins act on the same family of Npy receptors48,54, Pyy action might compensate the lack of Ppy expression. Yet, γ-cell ablation did not reveal any significant metabolic phenotype, implying that the putative compensatory Pyy effect should be due to the activity of intestinal L-cells, which secrete Pyy58,59. The generation of a conditional double Ppy-Pyy KO mouse would be required to elucidate the function of these Npy family peptidic hormones.
We recently reported that human γ-cells can be efficiently reprogrammed into glucose-responsive insulin-secreting cells upon Pdx1 and MafA overexpression44. Here, we confirmed this plasticity in vivo in mouse γ-cells. Like α- and δ-cells10,11, a small fraction of Ppy-expressing γ-cells (2–3%) spontaneously reprogram to produce insulin after extreme β-cell ablation. Like α- and δ-cells, the proportion of γ-cells that become insulin expressers can also be synergistically increased by forcing Pdx1 expression after β-cell ablation (up to 40%). Intriguingly, unlike α-cells, about half of the Pdx1+ γ-cells seemed refractory to reprogramming. This would be compatible with the heterogeneity observed here, and could indicate that the plasticity potential toward insulin production may be limited to a γ-cell subpopulation.
Systematic probing of cell populations with more sensitive methods will help expand our understanding of the versatile nature of cell identity. Whether cells with hybrid transcriptional character are also present throughout other organs, perhaps acting as functional cell reservoirs to be used in the direst of circumstances, remain open and very interesting questions. It is becoming apparent that cells exist in a continuum of functional and genetic states, which could contribute to how organisms adapt to the ever-changing environment.
Methods
Animals
In order to generate the Ppy-rtTA and Ppy-DTR knock-in mice, two regions of the Ppy locus were targeted with CRISPR: 5′-GGAGAGGCAGCAGTATGCGA-3′ and 5′-TGATTCCCTGCTCTGCGCCC-3′. These sequences comprise the ATG and STOP codon sides of the Ppy locus, respectively. The two targeted sgRNA were cloned into the Cas9-containing pX330 vector60. The donor plasmid (pBluescript II SK+) contained the rtTA (Tet-On 3G from Clontech) or DTR10,61 sequence flanked by 2 kb right homology arm (upstream of the ATG in Ppy locus) and 2 kb left homology arm (downstream of the STOP codon in Ppy locus). All three plasmids (two pX330 containing the sgRNA and the donor plasmid containing the rtTA sequence) were co-injected in one cell embryos. Ppy-rtTA transgene was combined with the previously described TetO-Cre, R26-YFP, RIP-DTR and CAG-STOP-Pdx162 transgenes.
Mice were housed in open cages with density varying depending on the size of the cage, in accordance with the Swiss regulation (Cage type S to L, Charles River). Cages were enriched with bedding, nestlet and a mouse house. Temperature and humidity in the housing room was maintained between 20–24 °C and 30–70%, respectively. The day-night cycles were programmed by alternating 12 h day–12 h night. Animals received food and tap water ad libitum.
Male and female mice were used in all experiments. Animals were randomly allocated to control or treatment groups. Because of γ-cell distribution and abundance, only ventral pancreas was analyzed. The study follows all ethical regulations regarding animal experimentation, all experiments were performed under the guidelines of the Direction General de la Santé du Canton de Genève (license numbers: GE/111/17 and GE/121/17).
Human samples
All studies involving human samples were approved by ethical committee in University of Geneva. Pancreatic histologic samples were obtained from anonymized deceased patients through the nPOD (Network for Pancreatic Organ Donors with Diabetes), supported by JDRF (Juvenile Diabetes Research Foundation International) at the U. of Florida. Donor information and consent from the donor family were obtained for all nPOD samples.
Diphtheria toxin, doxycycline, tamoxifen and insulin treatments
Diphtheria toxin (DT, Sigma) was injected intra-peritoneal (126 ng of DT per injection, on days 0, 3 and 4) to 2-month-old mice. Doxycycline (1 mg/ml; Sigma) was administered in the drinking water for two weeks. Tamoxifen (TAM, Sigma) was diluted (20 mg of TAM in 50 µl 100% ethanol and 950 µl corn oil) and injected intra-peritoneal (2 doses of 5 mg, 2 days apart) to 2-month-old mice. Mice received insulin pellet subcutaneously (Linbit) upon hyperglycemia (>25 mM).
Islet isolation, FACS and RNA extraction
Islet isolation and cell sorting using FACS were performed as described in previous work11,62 using a BD FACSAria II or Moflo Astrios (Beckman Coutler) system. FACSDiva v 8.0.1 (BD Biosciences) software was used for sorting on a FACSAria2, Summit v 6.2 (Beckman Coulter) for sorting on a Moflo Astrios. Kaluza Analysis v 2.0 (Beckman Coulter) software was used for subsequent analysis. Islets were frozen in RLT buffer (Qiagen) with β-Mercaptoethanol and stored at −80 °C before being processed for RNA extraction. RNA extraction from islets was prepared using the Qiagen RNeasy Micro Kit.
RT-qPCR
cDNA was generated using the Qiagen QuantiTect Reverse Transcription Kit. Total islets or YFP+ cells of Ppy-rtTA; R26-YFP mice were purified as described above. qPCR reactions were performed using the appropriate primers mixes for each gene as well as the Express SyBr© GreenER kit (Invitrogen #100001652). We used the CorbettRobotics4 robot and the PCR reaction was completed in the CorbettResearch6000 series cycler using a 40 cycles program. Normalization and analysis of the data were done with the RT-PCR analysis_macro v1.1 (from the Genomic Platform, University of Geneva) using two normalization genes (Gapdh and β-actin). Samples were run in triplicate. Primers sequences are shown in Supplementary Table 1.
Single cell RNA-sequencing
Islet cells were obtained from two-month-old doxycycline-treated Ppy-rtTA; R26-YFP mice. Islets were isolated and dissociated as described above. Two independent experiments were performed, containing islets from three and four mice, respectively. Single-cell dissociated islets were sorted on a Moflo Astrios (Beckman Coutler) system. Sorted YFP+ and YFP- cells of Ppy-rtTA; R26-YFP were loaded separately for single-cell RNA-seq using the Chromium Controller (10× Genomics) following the Single Cell 3′ Library kit v2 manufacture’s protocol. Libraries were sequenced as 100 bp paired-end reads on a HiSeq 40000 platform (Illumina). Reads were demultiplexed and counted using Cell Ranger software pipeline (v2.0.1; 10× Genomics) using Ensembl mm10 build 84 reference genome with the addition of YFP and rtTA transgenic sequences.
Data were loaded as Seurat objects (v3.1.0) in R (version 3.6.1) using R Studio (version 1.0.153) with the Read10X function. Positive and negative fractions from each replicate were combined into a single sparse matrix before being used to generate a Seurat object, with min.features set to 500. Cells were then filtered to contain at least 1000 UMIs and at most 7% mitochondrial genes. Data were normalized using the LogNormalize method, using 10’000 as scale factor. The top 1000 most variable genes were detected using the vst method after which all genes were scaled with use.umi set to TRUE, then principle component analysis (PCA) was performed to find the first 40 PCs.
Next, doublets were detected in each replicate using both DoubletFinder and Scrublet, assuming 2% doublets. In DoubletFinder, pN was set to 0.25 and pK to 0.30 (replicate 1) and 0.06 (replicate 2), according to parameter sweeps on each independent replicate. In Scrublet, the threshold for call_doublets was set to 0.2 for both replicates. Cells designated by either tool as a doublet were removed prior to downstream analysis.
At this point, both datasets were integrated using Seurat FindIntegrationAnchors function, using 20 CC’s. The integrated object was scaled with use.umi set to FALSE, the first 50 PCs were calculated and tested using jackstraw (all 50 were significant). Clustering was performed with a resolution of 0.1 after nearest neighbor detection. UMAP dimensional reduction was performed using the uwot method and the 30 nearest neighbors for local approximation. Differential expression between identities was calculated using the FindMarkers function in Seurat, using the negative binomial test on the RNA assay, with experiment replication set as a variable to regress, and a minimum log fold change set to 0.5. Marker genes were interpreted to determine which clusters consisted of endocrine cells, and the final dataset was filtered to contain just these cells. On this subset, PCA and UMAP dimensional reduction were rerun. Then, PCA, clustering and UMAP dimensional reduction were performed with a resolution of 0.8 after nearest neighbor detection.
For each of the four main hormones (Gcg, Ins2, Ppy and Sst), density plots were made of their expression distribution of normalized data in the entire dataset. This yielded bimodal plots, in which the local minima between modes could be mathematically determined, using a derivate function based on the bimodality_amplitude function of the modes package in R. Cells were assigned to be expressing any given hormone if its expression for that hormone was higher than the calculated local minimum value. Based on this method, each cell was assigned to express one or more hormones. The (combination of) expressed hormone(s) was used as an identity for downstream analysis. Only endocrine cells (hormone+ cells) were considered for further analysis. Any monohormonal and bihormonal Ppy-expressing cell not contained in its respective cluster was not included in the subsequent analysis.
Identity genes were generated by comparing mono-hormonal cell types in a pairwise manner (e.g., Gcg-expressing vs. Ins2-expressing, Ppy-expressing and Sst-expressing cells). Upregulated genes in bihormonal Ppy-expressing cells were calculated by comparing Ppy mono-hormonal cells with either Ppy-Gcg bi-hormonal cells, Ppy-Ins2 bi-hormonal cells or Ppy-Sst bi-hormonal cells, calculating differential expression as described above.
Isolation of human islet cell types
All studies involving human samples were approved by ethical committee in University of Geneva. Human islets from three independent non-diabetes donors were dissociated and stained with cell surface antibodies as described previously44–46. Briefly, labeled cells were sorted on a Moflo Astrios (Beckman Coulter) system. Doublet and dead cells were removed by forward scatter, side scatter, pulse-width parameters and negative staining for DAPI (D1306, Invitrogen). Single viable islet cells were gated in HIC3-2D12 vs. HIC1-2B4 plots and, then, in a CD9 vs. SSC-H plot. Endocrine cell fractions were processed using the Chromium single cell gene expression protocol v3 (10× Genomics).
Human islet single-cell transcriptome
Single data from Van Gurp et al. (submitted, under revision) was downloaded from GSE150724 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150724). Data were used as described in the original manuscript. Doublet cell removal using DoubletFinder and Scrublet was performed as described above. Differential expression was calculated as described above.
Pathway analysis
Pathway analysis was performed with ingenuity pathway analysis (IPA, QIAGEN, http://www.qiagen.com/ingenuity). DEGs between monohormonal Ppy+ vs monohormonal Gcg+, Ins2+ and Sst+-expressing cells were used for IPA analysis. DEGs were calculated as described above. IPA was performed using the following settings: expression value type (exp log ratio), reference set (ingenuity knowledge base), relationships to consider (direct and indirect relationships), interaction networks (35 molecules/network and 25 networks/analysis), data source (all), confidence (experimentally observed), species (human and mouse), tissue and cell lines (all), mutations (all).
Bulk transcriptomics analysis
Islet cells were obtained from two-month-old doxycycline or tamoxifen-treated Glucagon-rtTA; R26-YFP10 (Gcg-YFPi), SstCre; R26YFP11 (Sst-YFPi), RipCreER; R26YFP63 (RipCreER) and Ppy-rtTA; R26-YFP (Ppy-YFPi) mice. Islets were isolated and dissociated as described above. Cells were purified using a BD FACSAria II or Moflo Astrios (Beckman Coutler) system. RNA was extracted as described above and assessed for quality by Agilent bioanalyzer prior to library generation and sequencing. Libraries preparation, RNA-sequencing and quality controls were performed in the Genomics Core Facility of the University of Geneva. Reverse transcription and cDNA amplification were performed using the SMARTer Ultra Low RNA kit (Clontech). cDNA libraries were prepared using Nextera XT DNA Sample Preparation kit (Illumina) and sequenced on an Illumina HiSeq 2500 (for α-, β- and δ-cells) and HiSeq4000 platform (for γ-cells) with single-end 100-bp reads (for α-, β- and δ-cells) or pair-end 100 bp reads (for γ-cells).
All sequencing data were uploaded to, and aligned on the Galaxy project64 against Ensembl reference genome GRCm38.p6 (release 100) using STAR version 2.7.2b65 in 2-pass mapping mode. Aligned data were counted using HTSeq version 0.9.166 in union mode. Analyses were performed in a pair-wise manner between YFP-positive samples and alpha cell samples, YFP-positive samples and beta cell samples and YFP-positive samples and delta cell samples using DESeq2 version 1.28.167. For each pairwise comparison, genes were discarded if they had fewer than 5 counts per sample on average. After calculating differential expression between groups, log2 fold changes were shrunken using the normal estimator67. Genes were considered to be differentially expressed if the absolute shrunken log2 fold changes were equal to or above 1, and adjusted p values were equal to or below 0.05.
γ-ID genes were intersected with a published murine cell surfaceome study68 to obtain the γ-ID cell surface markers. Similarly, the γ-ID genes were intersected with the orthologues of the published human transcription factor atlas69 to obtain the γ-ID transcription factors.
i.p. glucose tolerance test
Mice were fasted for 16 h before starting the experiments. Intraperitoneal glucose tolerance test (ipGTT) was performed as described10. A 20% glucose solution was injected i.p. to fasted mice relative to their body weight. Glycemia was measured before the injection and 15, 30, 45, 60 and 120 min after glucose administration.
Immunofluorescence
Cryostat section were 10 µm thick. The primary antibodies used were: guinea pig anti-Pdx1 (1/750; C.W. Wright), guinea pig anti-porcine insulin (1/400; DAKO, A0564), rabbit anti-insulin (1/3000; Molecular Probes, 701265), mouse anti-glucagon (1/1000; Sigma, G2654), rabbit anti-glucagon (1/200; DAKO, A0565), mouse anti-somatostatin (1/200; BCBC Ab1985), rabbit anti-somatostatin (1/200; DAKO, A0566), goat anti-somatostatin (1/200; Santa Cruz Biotechnology, sc-55565), rabbit anti-GFP (1/400; Molecular Probes, A11122), chicken anti-GFP (1/500; Abcam, ab13970), mouse anti-Ppy (1/200; Y. Fujitani)70,mouse anti-Ppy (1/1000; R&D Biosystems, MAB62971), mouse anti-Pyy (1/1000; Abcam, ab112474), rabbit anti-Chga (1/200; Abcam, ab68271) and rabbit anti-Iapp (1/500; Abcam, ab254259). Secondary antibodies were coupled to Alexa 488, 405, 568, 647 (1/500; Molecular Probes) or TRITC, FITC, Cy3 and Cy5 (1/500; Southern Biotech). All antibodies are listed in Supplementary Table 2. Sections were also stained with DAPI. All sections were examined with a confocal microscope (Leica TCS SPE).
Statistics and reproducibility
Error bars represent s.d. or s.e.m as indicated in the figure legends. Statistical analyses were performed using Prism v8.0 software applying Mann–Whitney two-sided tests for comparison. P values are described in Figure Legends. Only the significant statistical differences are indicated in the figures. More than three mice per condition and experiment were analyzed as indicated in the figure legends and Supplementary Tables. Immunofluorescence was performed more than once for each mouse with >4 cryo-sections/mouse. The RNA-seq experiment/reaction was performed once (Fig. 4, Supplementary Fig. 9). The mouse single-cell RNA-seq experiment/reaction was performed twice (Figs. 4 and 5; Supplementary Figs. 7 and 9). The human single-cell RNA-seq experiment/reaction was performed three times based on tissue availability (Fig. 6, Supplementary Fig. 10). Quantitative PCRs were performed twice, using 3-8 individual biological samples as indicated in figure legends; each biological sample was run in triplicate (Figs. 2 and 7). Immunofluorescence for different antibodies was performed once for each mouse with more than 6 cryo-sections/animal being stained at once and analyzed (Figs. 1f, 2d, 6a, 7g, and 8g; Supplementary Figs. 1a, 2, 4a, f, 8, and 11c). The immunofluorescence reaction was repeated more ≥2 for Figs. 1d, 3a, 8d and Supplementary Figs. 3a, 5a, b, 12b.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Supplementary information
Acknowledgements
We thank G. Gallardo and C. Gysler for technical help, S. Chera for the scientific discussions, J.-P. Aubry-Lachainaye for FACS assistance and M. Docquier for RNA-sequencing advices and support. This work was funded with grants from the Swiss National Science Foundation (#310030_192496), the Fondation Aclon and the European Research Council (“Merlin”, #884449) to P.L.H. This research was performed with the support of the Network for Pancreatic Organ donors with Diabetes (nPOD; RRID:SCR_014641), a collaborative type 1 diabetes research project supported by JDRF (nPOD: 5-SRA-2018-557-Q-R) and The Leona M. & Harry B. Helmsley Charitable Trust (Grant # 2018PG-T1D053, G-2108-04793). The content and views expressed are the responsibility of the authors and do not necessarily reflect the official view of nPOD. Organ Procurement Organizations (OPO) partnering with nPOD to provide research resources are listed at http://www.jdrfnpod.org/for-partners/npod-partners/.”
Source data
Author contributions
M.P.F. conceived and performed the experiments and analyses, and wrote the manuscript; L.v.G analyzed all transcriptomic data, and edited the manuscript; M.V.A. performed and analyzed the gamma-cell ablation experiments; V.C. performed the alpha, beta and delta-cell bulk RNA-seq experiments; K.F. conceived the experiments, edited the manuscript, and generated the human islet scRNA-seq dataset; E.B.T contributed to the generation of the human islet scRNA-seq dataset, and edited the manuscript; D.O. contributed to discussions and wrote the manuscript; T.C contributed to the generation of the Ppy-rtTA mouse line; Y.F generated the Ppy antibody; F.T and P.L.H generated the Ppy-rtTA mouse line, conceived the experiments, interpreted the observations and wrote the manuscript.
Data availability
The mouse scRNA-seq and the gamma- and delta-cell bulk RNA-seq dataset generated in this study have been deposited in the NCBI GEO database with the accession number GSE156665. The mouse bulk-RNA-seq of alpha- and beta-cells was obtained from the NCBI GEO database (accession number GSE155519). The human scRNA-seq data are available under restricted access since it is not yet published, access can be obtained upon publication/request in the NCBI GEO database (accession number GSE150724).
Source data for Figs. 1–8 and Supplementary Information are provided with this paper in a Source Data file, availability of associated source data is indicated in each figure legend. Donor details for samples obtained through nPOD are available from the corresponding author upon reasonable request due to donor privacy.
All data and materials used are available from the authors or from commercially available sources. These data are available from corresponding author on reasonable request. Source data are provided with this paper.
Competing interests
The authors declare no competing interests.
Footnotes
Peer review informationNature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Change history
9/27/2021
A Correction to this paper has been published: 10.1038/s41467-021-26062-9
Supplementary information
The online version contains supplementary material available at 10.1038/s41467-021-24788-0.
References
- 1.Waldherr, S. Estimation methods for heterogeneous cell population models in systems biology. J. R. Soc. Interface15, 10.1098/rsif.2018.0530 (2018). [DOI] [PMC free article] [PubMed]
- 2.Altschuler SJ, Wu LF. Cellular heterogeneity: do differences make a difference? Cell. 2010;141:559–563. doi: 10.1016/j.cell.2010.04.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Fontaine R, Ager-Wick E, Hodne K, Weltzien FA. Plasticity in medaka gonadotropes via cell proliferation and phenotypic conversion. J. Endocrinol. 2020;245:21–37. doi: 10.1530/JOE-19-0405. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Fu Q, Vankelecom H. Regenerative capacity of the adult pituitary: multiple mechanisms of lactotrope restoration after transgenic ablation. Stem Cells Dev. 2012;21:3245–3257. doi: 10.1089/scd.2012.0290. [DOI] [PubMed] [Google Scholar]
- 5.Vidal S, et al. Transdifferentiation of somatotrophs to thyrotrophs in the pituitary of patients with protracted primary hypothyroidism. Virchows Arch. 2000;436:43–51. doi: 10.1007/pl00008197. [DOI] [PubMed] [Google Scholar]
- 6.Bruin JE, et al. Characterization of polyhormonal insulin-producing cells derived in vitro from human embryonic stem cells. Stem Cell Res. 2014;12:194–208. doi: 10.1016/j.scr.2013.10.003. [DOI] [PubMed] [Google Scholar]
- 7.Veres A, et al. Charting cellular identity during human in vitro β-cell differentiation. Nature. 2019;569:368–373. doi: 10.1038/s41586-019-1168-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ramond, C. et al. Understanding human fetal pancreas development using subpopulation sorting, RNA sequencing and single-cell profiling. Development, 145, 10.1242/dev.165480 (2018). [DOI] [PMC free article] [PubMed]
- 9.Md Moin AS, et al. Increased hormone-negative endocrine cells in the pancreas in type 1 diabetes. J. Clin. Endocrinol. Metab. 2016;101:3487–3496. doi: 10.1210/jc.2016-1350. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Thorel F, et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature. 2010;464:1149–1154. doi: 10.1038/nature08894. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Chera S, et al. Diabetes recovery by age-dependent conversion of pancreatic δ-cells into insulin producers. Nature. 2014;514:503–507. doi: 10.1038/nature13633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Svendsen B, et al. Insulin secretion depends on intra-islet glucagon signaling. Cell Rep. 2018;25:1127–1134.e1122. doi: 10.1016/j.celrep.2018.10.018. [DOI] [PubMed] [Google Scholar]
- 13.Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology. 2000;141:111–117. doi: 10.1210/endo.141.1.7263. [DOI] [PubMed] [Google Scholar]
- 14.Vergari E, et al. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion. Nat. Commun. 2019;10:139. doi: 10.1038/s41467-018-08193-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Li N, et al. Ablation of somatostatin cells leads to impaired pancreatic islet function and neonatal death in rodents. Cell Death Dis. 2018;9:682. doi: 10.1038/s41419-018-0741-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Folli F, et al. Pancreatic islet of Langerhans’ cytoarchitecture and ultrastructure in normal glucose tolerance and in type 2 diabetes mellitus. Diabetes Obes. Metab. 2018;20:137–144. doi: 10.1111/dom.13380. [DOI] [PubMed] [Google Scholar]
- 17.Da Silva Xavier, G. The cells of the islets of Langerhans. J. Clin. Med.7, 10.3390/jcm7030054 (2018). [DOI] [PMC free article] [PubMed]
- 18.Anık A, Çatlı G, Abacı A, Böber E. Maturity-onset diabetes of the young (MODY): an update. J. Pediatr. Endocrinol. Metab. 2015;28:251–263. doi: 10.1515/jpem-2014-0384. [DOI] [PubMed] [Google Scholar]
- 19.Fujimiya M, Inui A. Peptidergic regulation of gastrointestinal motility in rodents. Peptides. 2000;21:1565–1582. doi: 10.1016/s0196-9781(00)00313-2. [DOI] [PubMed] [Google Scholar]
- 20.Ting CH, Chen YC, Liaw WJ, Lin HC, Chen CY. Peripheral injection of pancreatic polypeptide enhances colonic transit without eliciting anxiety or altering colonic secretion in rats. Neuropeptides. 2016;55:67–71. doi: 10.1016/j.npep.2015.10.002. [DOI] [PubMed] [Google Scholar]
- 21.Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides. 2012;46:261–274. doi: 10.1016/j.npep.2012.08.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Asakawa A, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology. 2003;124:1325–1336. doi: 10.1016/s0016-5085(03)00216-6. [DOI] [PubMed] [Google Scholar]
- 23.Verschueren S, Janssen P, Van Oudenhove L, Hultin L, Tack J. Effect of pancreatic polypeptide on gastric accommodation and gastric emptying in conscious rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2014;307:G122–G128. doi: 10.1152/ajpgi.00043.2014. [DOI] [PubMed] [Google Scholar]
- 24.Schmidt PT, et al. A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J. Clin. Endocrinol. Metab. 2005;90:5241–5246. doi: 10.1210/jc.2004-2089. [DOI] [PubMed] [Google Scholar]
- 25.Batterham RL, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J. Clin. Endocrinol. Metab. 2003;88:3989–3992. doi: 10.1210/jc.2003-030630. [DOI] [PubMed] [Google Scholar]
- 26.Ueno N, et al. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology. 1999;117:1427–1432. doi: 10.1016/s0016-5085(99)70293-3. [DOI] [PubMed] [Google Scholar]
- 27.Wortley KE, et al. Peptide YY regulates bone turnover in rodents. Gastroenterology. 2007;133:1534–1543. doi: 10.1053/j.gastro.2007.08.024. [DOI] [PubMed] [Google Scholar]
- 28.Schonhoff S, et al. Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol. Cell Biol. 2005;25:4189–4199. doi: 10.1128/MCB.25.10.4189-4199.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Omar-Hmeadi M, Lund PE, Gandasi NR, Tengholm A, Barg S. Paracrine control of α-cell glucagon exocytosis is compromised in human type-2 diabetes. Nat. Commun. 2020;11:1896. doi: 10.1038/s41467-020-15717-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Rorsman P, Huising MO. The somatostatin-secreting pancreatic δ-cell in health and disease. Nat. Rev. Endocrinol. 2018;14:404–414. doi: 10.1038/s41574-018-0020-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Brissova M, et al. α cell function and gene expression are compromised in type 1 diabetes. Cell Rep. 2018;22:2667–2676. doi: 10.1016/j.celrep.2018.02.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Srinivas S, et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 2001;1:4. doi: 10.1186/1471-213X-1-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Perl AK, Wert SE, Nagy A, Lobe CG, Whitsett JA. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc. Natl Acad. Sci. USA. 2002;99:10482–10487. doi: 10.1073/pnas.152238499. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Ekblad E, Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides. 2002;23:251–261. doi: 10.1016/s0196-9781(01)00601-5. [DOI] [PubMed] [Google Scholar]
- 35.Wang X, et al. Quantitative analysis of pancreatic polypeptide cell distribution in the human pancreas. PLoS One. 2013;8:e55501. doi: 10.1371/journal.pone.0055501. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Herrera PL, et al. Ablation of islet endocrine cells by targeted expression of hormone-promoter-driven toxigenes. Proc. Natl Acad. Sci. USA. 1994;91:12999–13003. doi: 10.1073/pnas.91.26.12999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development. 2000;127:2317–2322. doi: 10.1242/dev.127.11.2317. [DOI] [PubMed] [Google Scholar]
- 38.Herrera PL, et al. Embryogenesis of the murine endocrine pancreas; early expression of pancreatic polypeptide gene. Development. 1991;113:1257–1265. doi: 10.1242/dev.113.4.1257. [DOI] [PubMed] [Google Scholar]
- 39.Huang YH, Sun MJ, Jiang M, Fu BY. Immunohistochemical localization of glucagon and pancreatic polypeptide on rat endocrine pancreas: coexistence in rat islet cells. Eur. J. Histochem. 2009;53:e10. doi: 10.4081/ejh.2009.e10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Aragón F, et al. Pancreatic polypeptide regulates glucagon release through PPYR1 receptors expressed in mouse and human alpha-cells. Biochim Biophys. Acta. 2015;1850:343–351. doi: 10.1016/j.bbagen.2014.11.005. [DOI] [PubMed] [Google Scholar]
- 41.Teitelman G, Alpert S, Polak JM, Martinez A, Hanahan D. Precursor cells of mouse endocrine pancreas coexpress insulin, glucagon and the neuronal proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic polypeptide. Development. 1993;118:1031–1039. doi: 10.1242/dev.118.4.1031. [DOI] [PubMed] [Google Scholar]
- 42.McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: doublet detection in single-cell rna sequencing data using artificial nearest neighbors. Cell Syst. 2019;8:329–337.e324. doi: 10.1016/j.cels.2019.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Wolock SL, Lopez R, Klein AM. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 2019;8:281–291.e289. doi: 10.1016/j.cels.2018.11.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Furuyama K, et al. Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. Nature. 2019;567:43–48. doi: 10.1038/s41586-019-0942-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Bramswig NC, et al. Epigenomic plasticity enables human pancreatic α to β cell reprogramming. J. Clin. Invest. 2013;123:1275–1284. doi: 10.1172/JCI66514. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Dorrell C, et al. Human islets contain four distinct subtypes of β cells. Nat. Commun. 2016;7:11756. doi: 10.1038/ncomms11756. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Atanes P, et al. Defining G protein-coupled receptor peptide ligand expressomes and signalomes in human and mouse islets. Cell Mol. Life Sci. 2018;75:3039–3050. doi: 10.1007/s00018-018-2778-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Pedragosa-Badia X, Stichel J, Beck-Sickinger AG. Neuropeptide Y receptors: how to get subtype selectivity. Front Endocrinol. (Lausanne) 2013;4:5. doi: 10.3389/fendo.2013.00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Brothers SP, Wahlestedt C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol. Med. 2010;2:429–439. doi: 10.1002/emmm.201000100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Yuzuriha H, et al. Development of pancreatic islets in pancreatic polypeptide-overexpressing mice. Int J. Mol. Med. 2004;14:201–205. [PubMed] [Google Scholar]
- 51.Upchurch BH, Aponte GW, Leiter AB. Expression of peptide YY in all four islet cell types in the developing mouse pancreas suggests a common peptide YY-producing progenitor. Development. 1994;120:245–252. doi: 10.1242/dev.120.2.245. [DOI] [PubMed] [Google Scholar]
- 52.Lee NJ, et al. Synergistic attenuation of obesity by Y2- and Y4-receptor double knockout in ob/ob mice. Nutrition. 2008;24:892–899. doi: 10.1016/j.nut.2008.06.019. [DOI] [PubMed] [Google Scholar]
- 53.Lin S, et al. Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice. PLoS One. 2009;4:e8488. doi: 10.1371/journal.pone.0008488. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Cerdá-Reverter JM, Larhammar D. Neuropeptide Y family of peptides: structure, anatomical expression, function, and molecular evolution. Biochem Cell Biol. 2000;78:371–392. [PubMed] [Google Scholar]
- 55.Shi YC, et al. PYY3-36 and pancreatic polypeptide reduce food intake in an additive manner via distinct hypothalamic dependent pathways in mice. Obesity. 2013;21:E669–E678. doi: 10.1002/oby.20534. [DOI] [PubMed] [Google Scholar]
- 56.Hort Y, Baker E, Sutherland GR, Shine J, Herzog H. Gene duplication of the human peptide YY gene (PYY) generated the pancreatic polypeptide gene (PPY) on chromosome 17q21.1. Genomics. 1995;26:77–83. doi: 10.1016/0888-7543(95)80085-z. [DOI] [PubMed] [Google Scholar]
- 57.Conlon JM. The origin and evolution of peptide YY (PYY) and pancreatic polypeptide (PP) Peptides. 2002;23:269–278. doi: 10.1016/s0196-9781(01)00608-8. [DOI] [PubMed] [Google Scholar]
- 58.Karra E, Chandarana K, Batterham RL. The role of peptide YY in appetite regulation and obesity. J. Physiol. 2009;587:19–25. doi: 10.1113/jphysiol.2008.164269. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Habib AM, Richards P, Rogers GJ, Reimann F, Gribble FM. Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. Diabetologia. 2013;56:1413–1416. doi: 10.1007/s00125-013-2887-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819–823. doi: 10.1126/science.1231143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Saito M, et al. Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat. Biotechnol. 2001;19:746–750. doi: 10.1038/90795. [DOI] [PubMed] [Google Scholar]
- 62.Cigliola V, et al. Pancreatic islet-autonomous insulin and smoothened-mediated signalling modulate identity changes of glucagon(+) α-cells. Nat. Cell Biol. 2018;20:1267–1277. doi: 10.1038/s41556-018-0216-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature. 2004;429:41–46. doi: 10.1038/nature02520. [DOI] [PubMed] [Google Scholar]
- 64.Afgan E, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res. 2018;46:W537–w544. doi: 10.1093/nar/gky379. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. doi: 10.1093/bioinformatics/bts635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166–169. doi: 10.1093/bioinformatics/btu638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Bausch-Fluck D, et al. A mass spectrometric-derived cell surface protein atlas. PLoS One. 2015;10:e0121314. doi: 10.1371/journal.pone.0121314. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Lambert SA, et al. The human transcription factors. Cell. 2018;175:598–599. doi: 10.1016/j.cell.2018.09.045. [DOI] [PubMed] [Google Scholar]
- 70.Hara A, et al. Development of monoclonal mouse antibodies that specifically recognize pancreatic polypeptide. Endocr. J. 2019;66:459–468. doi: 10.1507/endocrj.EJ18-0441. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The mouse scRNA-seq and the gamma- and delta-cell bulk RNA-seq dataset generated in this study have been deposited in the NCBI GEO database with the accession number GSE156665. The mouse bulk-RNA-seq of alpha- and beta-cells was obtained from the NCBI GEO database (accession number GSE155519). The human scRNA-seq data are available under restricted access since it is not yet published, access can be obtained upon publication/request in the NCBI GEO database (accession number GSE150724).
Source data for Figs. 1–8 and Supplementary Information are provided with this paper in a Source Data file, availability of associated source data is indicated in each figure legend. Donor details for samples obtained through nPOD are available from the corresponding author upon reasonable request due to donor privacy.
All data and materials used are available from the authors or from commercially available sources. These data are available from corresponding author on reasonable request. Source data are provided with this paper.